Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis Clinical Trial

— CLEAR-PS  

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03358290
• Other study ID #: AE051-G-16-007
• Status: Terminated
• Phase: Phase 2
• Start date: November 10, 2017
• Est. completion date: October 29, 2018

Study information

• Verified date: July 2021
• Source: Akros Pharma Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: October 29, 2018
• Est. primary completion date: October 29, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1

• Plaque-type psoriasis covering =10% of body surface area (BSA) at Visit 1 and Visit 2;

• Psoriasis Area and Severity Index (PASI) score =12 at Visit 1 and Visit 2;

• Static Physician's Global Assessment (sPGA) score =3 at Visit 1 and Visit 2;

• Body Mass Index (BMI) =40 at Visit 1.

Exclusion Criteria:

• Medical history of treatment failure to any systemic agents for plaque psoriasis;

• Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions at (e.g., clinically-significant eczema or severe acne) that could interfere with study evaluations at Visit 1;

• Presence or history of any itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin (e.g., drug induced pruritus, significant other systemic diseases with itch) within 12 months prior to Visit 1;

• History of a clinically-significant infection (e.g., that required oral antimicrobial therapy) within 8 weeks prior to Visit 2;

• History of infections requiring hospitalization or parenteral antibiotic, antiviral, antifungal or antiparasitic therapy within 6 months prior to Visit 2 and no history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis);

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis
• Skin Diseases

Intervention

Drug:
• JTE-051
Active drug tablets containing JTE-051
• Placebo
Placebo tablets identical in appearance to the active drug tablets

Locations

Country	Name	City	State
Canada	Mediprobe Research Inc.	London	Ontario
Canada	Lynderm Research Inc.	Markham	Ontario
Canada	David Gratton's Private Practice	Montreal	Quebec
Canada	Karma Clinical Trials	Saint John's	Newfoundland and Labrador
United States	Atlanta Dermatology Vein and Research Center LLC	Alpharetta	Georgia
United States	Radiant Research, Inc.	Anderson	South Carolina
United States	Clinical Research Center of the Carolinas	Charleston	South Carolina
United States	Dermatology Treatment and Research Center	Dallas	Texas
United States	Clinical Research Advantage, Inc.	Evansville	Indiana
United States	Forest Hills Dermatology Group	Forest Hills	New York
United States	First OC Dermatology	Fountain Valley	California
United States	Center For Dermatology Clinical Research, Inc.	Fremont	California
United States	Advanced Clinical Research - Dermatology Center of Canyon County	Nampa	Idaho
United States	Kansas City Dermatology P.A.	Overland Park	Kansas
United States	Advanced Medical Research, PC	Sandy Springs	Georgia
United States	University of South Florida - Hospital	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Akros Pharma Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT).	The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks).; The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.; The PASI-75 response rate is defined as at least 75 percent (%) reduction in PASI score relative to Baseline.	Up to 12 Weeks
Secondary	Percent Change From Baseline in PASI Score	The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks).; The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.; Percent change was calculated by taking the Week 12 PASI score and subtracting the baseline PASI, and dividing by the baseline PASI, then multiplying by 100 to get the percent change from baseline.	Week 12
Secondary	Proportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI)	The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks).; The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.; The PASI-50 response rate is defined as at least 50 percent (%) reduction in PASI score relative to Baseline.	Week 12
Secondary	Proportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI)	The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks).; The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.; The PASI-90 response rate is defined as at least 90 percent (%) reduction in PASI score relative to Baseline.	Week 12
Secondary	Proportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI)	The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks).; The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.; The PASI-100 response rate is defined as 100 percent (%) reduction in PASI score relative to Baseline.	Week 12
Secondary	Proportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1	The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe).; For this outcome measure, a score of 0 means no symptoms of psoriasis and a score of 1 means minimal symptoms of psoriasis.	Week 12
Secondary	Change From Baseline in Static Physician's Global Assessment (sPGA) Score	The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe).; Change from baseline to Week 12 in sPGA was calculated by taking the Week 12 sPGA and subtracting the baseline sPGA.	Week 12
Secondary	Percent Change From Baseline in Psoriasis Body Surface Area (BSA)	The total body surface area (BSA) affected by plaque-type psoriasis was obtained from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) and the resulting 4 values were added up to obtain the total psoriasis BSA (Range: 0 to 100).; BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region surface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.; Percent change from baseline to Week 12 in BSA was calculated by taking the Week 12 BSA and subtracting the baseline BSA, then dividing by the baseline BSA and multiplying by 100.; A negative change from baseline at Week 12 indicates a reduction in the Psoriasis BSA compared to the baseline.	Week 12
Secondary	Change From Baseline in the Skindex-16 Overall Score	Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional & functional; their respective scores are expressed in a linear scale from 0 to 100. Overall scale score is an average of 16 items expressed in a linear scale from 0 to 100.; Change from baseline to Week 12 in the Skindex-16 Overall Score was calculated by taking the Week 12 Skindex-16 Overall Score and subtracting the baseline Skindex-16 Overall Score.; A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.	Week 12
Secondary	Change From Baseline in the Skindex-16 Symptoms Scale Score	Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional & functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score is an average of items 1 to 4 expressed in a linear scale from 0 to 100.; Change from baseline to Week 12 in the Skindex-16 Symptoms Scale Score was calculated by taking the Week 12 Skindex-16 Symptoms Scale Score and subtracting the baseline Skindex-16 Symptoms Scale Score.; A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.	Week 12
Secondary	Change From Baseline in the Skindex-16 Emotions Scale Score	Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional & functional; their respective scores are expressed in a linear scale from 0 to 100. Emotions scale score is an average of items 5 to 11 expressed in a linear scale from 0 to 100.; Change from baseline to Week 12 in the Skindex-16 Emotions Scale Score was calculated by taking the Week 12 Skindex-16 Emotions Scale Score and subtracting the baseline Skindex-16 Emotions Scale Score.; A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.	Week 12
Secondary	Change From Baseline in the Skindex-16 Functioning Scale Score	Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional & functional; their respective scores are expressed in a linear scale from 0 to 100. Functioning scale score is an average of items 12 to 16 expressed in a linear scale from 0 to 100.; Change from baseline to Week 12 in the Skindex-16 Functioning Scale Score was calculated by taking the Week 12 Skindex-16 Functioning Scale Score and subtracting the baseline Skindex-16 Functioning Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.	Week 12
Secondary	Number of Subjects With Treatment-emergent Adverse Events	Subjects in the Safety Population (13, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The study was terminated early as per the Sponsor decision. All randomized subjects were included in the Safety Population.	Up to 16 Weeks
Secondary	JTE-051 Trough Plasma Concentrations	Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTE-051 in the subjects randomized to JTE-051 treatment groups.	Week 12